Far-East Scarlet-Like Fever

Infectious Disease MONDO:0041536 Pathograph 18 Show in embeddings browser Yersinia Pseudotuberculosis Infectious Disease

Far-East scarlet-like fever is the severe Far Eastern systemic inflammatory form of Yersinia pseudotuberculosis infection, in which epidemic YPMa-superantigen-producing strains trigger Vbeta-restricted T-cell activation and a Kawasaki-like illness with fever, rash, desquamation, conjunctivitis, strawberry tongue, cheilitis, enteric symptoms, and arthralgia.

Ask OpenScientist

Ask a research question about Far-East Scarlet-Like Fever. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
6
Pathophys.
12
Phenotypes
18
Pathograph
2
Medical Actions
1
Deep Research
📘

Definitions

1
Far-East scarlet-like fever syndrome
FESLF is the severe systemic inflammatory disease variant caused by Far Eastern Y. pseudotuberculosis strains, historically recognized in Russian Far East and Japanese outbreak settings as Izumi fever-like or Kawasaki-like pseudotuberculosis.
CASE_DEFINITION
Show evidence (1 reference)
PMID:26819960 SUPPORT REVIEW SYNTHESIS Other
"Far East scarlet-like fever (FESLF) is a severe inflammatory disease that occurs sporadically and in outbreaks in Russia and Japan."
The review defines FESLF as the severe Far Eastern inflammatory disease variant of Y. pseudotuberculosis infection.
⚙

Pathophysiology

6
Far Eastern YPMa Superantigen Production
The defining bacterial input is a Far Eastern Y. pseudotuberculosis lineage that expresses the secreted YPMa superantigen, redirecting infection from localized gastroenteritis toward systemic FESLF inflammation.
Downstream
Superantigenic MHC-II and TCR Vbeta Engagement YPM engages MHC class II and T-cell receptor Vbeta surfaces rather than a conventional peptide-specific TCR groove.
Show evidence (1 reference)
PMID:26819960 SUPPORT REVIEW SYNTHESIS Other
"Geographical heterogeneity exists between virulence factors produced by European and Far Eastern Y pseudotuberculosis strains, implicating superantigen Y pseudotuberculosis-derived mitogen A (YPMa) in the pathogenesis of FESLF."
The review places YPMa specifically in the Far Eastern virulence program implicated in FESLF.
Superantigenic MHC-II and TCR Vbeta Engagement
YPM binds the Vbeta surface of T-cell receptors in a way that bypasses ordinary antigen specificity; point mutants defective in Vbeta binding show parallel attenuation of T-cell proliferation, cytotoxic activation, and proinflammatory cytokine release.
T cell receptor signaling pathway GO:0050852 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves T cell receptor signaling pathway (GO:0050852). GO:0050852 is a biological process from the Gene Ontology.
Downstream
Vbeta-Restricted T Cell Activation TCR Vbeta binding converts the secreted bacterial mitogen into nonclonal, Vbeta-restricted T-cell stimulation.
Show evidence (1 reference)
PMID:10406939 SUPPORT In Vitro
"Finally, we obtained evidence that YPM partially competes with staphylococcal enterotoxin E for human leukocyte antigen-DR binding."
In-vitro binding studies support HLA-DR engagement as part of the YPM superantigen mechanism.
Vbeta-Restricted T Cell Activation
In vivo exposure to YPM expands Vbeta-biased alpha-beta T cells; experimental YPM shock depends on CD4-positive, TCR Vbeta7/Vbeta8 T cells rather than on conventional antigen-specific T-cell priming.
CD4-positive, alpha-beta T cell CL:0000624 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4-positive, alpha-beta T cell (CL:0000624). CL:0000624 is a cell type from the Cell Ontology.
T cell activation GO:0042110 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased T cell activation (GO:0042110). GO:0042110 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
YPM-Induced Proinflammatory Cytokine Production Activated Vbeta-restricted T cells drive TNF-alpha and IFN-gamma release, producing a shock-like inflammatory effector arm.
Superantigen-Activated T Cell Liver Homing YPM-activated Vbeta-biased T cells can rapidly traffic from blood into the liver in a superantigen shock model.
Show evidence (1 reference)
PMID:9109426 SUPPORT Human Clinical
"T cells bearing the Vbeta3 gene segment were significantly increased (P = 0.009) among acute phase patients compared with healthy children."
The human acute-infection series supports Vbeta-biased T-cell expansion during Y. pseudotuberculosis infection.
YPM-Induced Proinflammatory Cytokine Production
YPM-triggered T cells and peripheral blood leukocytes release proinflammatory cytokines, including TNF-alpha and interferon-gamma, forming a measured cellular effector response downstream of superantigenic T-cell activation.
alpha-beta T cell CL:0000789 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves alpha-beta T cell (CL:0000789). CL:0000789 is a cell type from the Cell Ontology.
cytokine production GO:0001816 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cytokine production (GO:0001816). GO:0001816 is a biological process from the Gene Ontology. ↑ INCREASED type II interferon production GO:0032609 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased type II interferon production (GO:0032609). GO:0032609 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
FESLF Mucocutaneous and Systemic Inflammatory Syndrome YPM-triggered cytokine release is the superantigen effector arm that links Vbeta-restricted T-cell activation to the systemic FESLF syndrome.
Show evidence (2 references)
PMID:15003813 SUPPORT INDIRECT Model Organism
"We found that Vbeta8(+) T cells activated by YPM migrated from peripheral blood to liver as early as 1 h after injection of YPM and that serum level of IFN-gamma was significantly elevated 4 h after YPM injection."
The mouse YPM shock model supports rapid Vbeta-biased T-cell activation followed by systemic IFN-gamma release.
PMID:12449699 SUPPORT In Vitro
"The maximum stimulation of the production of cytokines was observed under the action of YPM, which confirmed an important role played by this superantigen in the pathogenesis of Y. pseudotuberculosis."
Human whole-blood stimulation supports YPM as a potent cytokine-inducing superantigen.
FESLF Mucocutaneous and Systemic Inflammatory Syndrome
YPMa-positive systemic inflammation in children presents as an Izumi fever-like and Kawasaki-like syndrome with frequent fever, rash, mucocutaneous findings, gastrointestinal symptoms, arthralgia, and, in a Kawasaki-presenting subset, coronary artery lesions.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Fever Fever belongs to the frequent systemic FESLF presentation.
Skin Rash Rash belongs to the frequent mucocutaneous FESLF presentation.
Diarrhea Diarrhea belongs to the frequent gastrointestinal FESLF presentation.
Desquamation Desquamation belongs to the frequent mucocutaneous FESLF presentation.
Strawberry Tongue Strawberry tongue belongs to the frequent oral mucosal FESLF presentation.
Vomiting Vomiting belongs to the frequent gastrointestinal FESLF presentation.
Red and Cracked Lips Cracked erythematous lips belong to the frequent oral mucosal FESLF presentation.
Abdominal Pain Abdominal pain belongs to the frequent gastrointestinal FESLF presentation.
Arthralgia Arthralgia belongs to the frequent systemic FESLF presentation.
Conjunctivitis Conjunctivitis belongs to the frequent mucocutaneous FESLF presentation.
Coronary Artery Lesions Kawasaki disease with evidence of Y. pseudotuberculosis infection has an enriched coronary artery lesion burden.
Show evidence (2 references)
PMID:6344044 SUPPORT Human Clinical
"Additionally the finding in two children fulfilled the strict criteria for Kawasaki syndrome, and signs in the other 10 children were consistent with that diagnosis."
The pediatric series documents that the common FESLF mucocutaneous and systemic findings clinically overlapped Kawasaki syndrome.
PMID:26819960 SUPPORT REVIEW SYNTHESIS Other
"Studies suggest the ability of Far Eastern strains to produce superantigen toxin Y pseudotuberculosis-derived mitogen A is integral to FESLF pathogenesis."
Review-level evidence supports YPMa-driven superantigen inflammation as integral to the systemic FESLF syndrome.
Superantigen-Activated T Cell Liver Homing
YPM can recruit Vbeta-biased T cells into the liver in vivo, providing a model-organism bridge from the superantigenic T-cell node to the liver enlargement observed in pediatric FESLF.
CD4-positive, alpha-beta T cell CL:0000624 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD4-positive, alpha-beta T cell (CL:0000624). CL:0000624 is a cell type from the Cell Ontology.
Downstream
Hepatomegaly Hepatic trafficking of YPM-activated T cells provides a plausible superantigen-linked bridge to hepatomegaly in FESLF.
Show evidence (1 reference)
PMID:15003813 SUPPORT INDIRECT Model Organism
"Vbeta8(+) T cells activated by YPM migrated from peripheral blood to liver"
The model directly measures YPM-activated Vbeta-biased T-cell migration into liver after superantigen exposure.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Far-East Scarlet-Like Fever Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Cardiovascular 2
Conjunctivitis FREQUENT HP:0000509 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Conjunctivitis (HP:0000509). HP:0000509 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports conjunctivitis among common FESLF-like mucocutaneous findings.
Coronary Artery Lesions FREQUENT Coronary artery aneurysm HP:0030882 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Coronary artery aneurysm (HP:0030882). HP:0030882 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17129979 SUPPORT Human Clinical
"the incidence of coronary artery lesions (dilatations plus aneurysms) in the Yersinia-positive group (22/42, 52.4%) was significantly higher than in the Yersinia-negative group (105/330, 31.8%) (p=0.001)"
Coronary dilatations or aneurysms occurred in 52.4% of Yersinia-positive Kawasaki disease cases, supporting the FREQUENT band for Kawasaki-presenting FESLF.
Digestive 3
Diarrhea FREQUENT HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series found diarrhea in at least half of Y. pseudotuberculosis patients with FESLF-like illness.
Vomiting FREQUENT HP:0002013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vomiting (HP:0002013). HP:0002013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series found vomiting in at least half of patients.
Hepatomegaly FREQUENT HP:0002240 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatomegaly (HP:0002240). HP:0002240 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series found hepatomegaly in at least half of patients.
Head and Neck 2
Strawberry Tongue FREQUENT HP:0031042 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Strawberry tongue (HP:0031042). HP:0031042 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports strawberry tongue among common FESLF-like oral findings.
Red and Cracked Lips FREQUENT Cheilitis HP:0100825 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is red and cracked lips, annotated with Cheilitis (HP:0100825). HP:0100825 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports red and cracked lips among common oral mucosal findings.
Immune 1
Skin Rash FREQUENT HP:0000988 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skin rash (HP:0000988). HP:0000988 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports rash among common findings in Y. pseudotuberculosis illness resembling Izumi fever.
Integument 1
Desquamation FREQUENT Scaling skin HP:0040189 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is desquamation, annotated with Scaling skin (HP:0040189). HP:0040189 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports desquamation among the common mucocutaneous findings.
Metabolism 1
Fever FREQUENT HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The 12-child clinical series found fever in at least half of patients with Y. pseudotuberculosis infection resembling Izumi fever and Kawasaki syndrome.
Constitutional 2
Abdominal Pain FREQUENT HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series found abdominal pain in at least half of patients.
Arthralgia FREQUENT HP:0002829 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arthralgia (HP:0002829). HP:0002829 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis."
The pediatric series reports arthralgias among common findings.
💊

Medical Actions

2
Organism-directed antibiotic therapy
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: cefotaxime CHEBI:204928 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cefotaxime (CHEBI:204928). CHEBI:204928 is a therapeutic agent from Chemical Entities of Biological Interest. imipenem CHEBI:471744 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses imipenem (CHEBI:471744). CHEBI:471744 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Antibiotic therapy should be considered for severe, septicemic, or persistent Kawasaki-like Y. pseudotuberculosis disease once FESLF is suspected or confirmed.
Show evidence (2 references)
PMID:39697956 SUPPORT Human Clinical
"Based on these findings, cefotaxime was re-administered. The patient defervesced the next day and was afebrile late on with the improvement of inflammatory markers."
The refractory Kawasaki-like pediatric case improved after cefotaxime was restarted for the underlying Y. pseudotuberculosis infection.
PMID:18411766 SUPPORT Human Clinical
"After chemotherapy with imipenem, subjective symptoms ameliorated."
This septicemic Y. pseudotuberculosis case supports antibiotic treatment for severe invasive disease.
IVIG and aspirin for Kawasaki-presenting disease
Action: intravenous immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is intravenous immunoglobulin therapy (NCIT:C121331). NCIT:C121331 is a clinical intervention from the NCI Thesaurus. Ontology label: Intravenous Immunoglobulin Therapy NCIT:C121331
Agent: Therapeutic Immune Globulin NCIT:C2701 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Therapeutic Immune Globulin (NCIT:C2701). NCIT:C2701 is a therapeutic agent from the NCI Thesaurus. aspirin CHEBI:15365 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses aspirin, annotated with acetylsalicylic acid (CHEBI:15365). CHEBI:15365 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Other
Kawasaki-presenting FESLF may require standard Kawasaki disease therapy with IVIG and aspirin to control vasculitis and limit coronary complications, while remaining alert to Yersinia-associated IVIG resistance.
Show evidence (2 references)
PMID:17129979 SUPPORT Human Clinical
"the incidence of additional administration of immunoglobulin in the Yersinia-positive group (13/36, 36.1%) was significantly higher than in the Yersinia-negative group (41/256, 16.0%) (p=0.004)."
Yersinia-positive Kawasaki disease patients more often needed additional immunoglobulin, supporting IVIG relevance and resistance risk in this subset.
PMID:39697956 SUPPORT BACKGROUND Other
"Treatment includes intravenous immunoglobulin (IVIG) and aspirin to reduce complications, especially coronary artery issues."
The Kawasaki/Yersinia case report restates IVIG plus aspirin as standard Kawasaki disease treatment for reducing coronary complications.
🔬

Diagnosis

2
Stool culture and paired agglutinating antibody titers
Pediatric FESLF-like disease can be confirmed by recovering Y. pseudotuberculosis from stool and documenting a fourfold or greater change in agglutinating antibody titer; stool isolates may require cold enrichment.
Show evidence (2 references)
PMID:6344044 SUPPORT Human Clinical
"Yersinia pseudotuberculosis infection was diagnosed in 12 children on the basis of recovery of the organism from stool cultures and a 4-fold or greater titer change in agglutinating antibody."
The pediatric Izumi/Kawasaki-like series anchors stool culture and paired serology as confirmatory tests.
PMID:6344044 SUPPORT Human Clinical
"Eight of the 12 Yersinia isolates were recovered from stool cultures only after cold enrichment."
The same series documents that most stool isolates needed cold enrichment before recovery.
Yersinia agglutination serology in refractory Kawasaki-like illness
In Kawasaki-like presentations that persist despite immunomodulatory treatment, paired Yersinia agglutination titers can confirm infection even when blood and stool cultures are unrevealing.
Show evidence (1 reference)
PMID:39697956 SUPPORT Human Clinical
"Although stool and blood cultures did not detect any significant pathogens, analysis of Yersinia serum agglutinin titers revealed a result below detectable sensitivity on the second day of illness and a 640-fold increase on the 17th day."
The Kawasaki-presenting case illustrates serologic confirmation after negative cultures.
📈

Progression

2
YPMa-positive systemic inflammatory yersiniosis
Far Eastern strains enter the superantigen-driven branch of Y. pseudotuberculosis infection rather than remaining a purely localized enteric illness.
Show evidence (1 reference)
PMID:26819960 SUPPORT REVIEW SYNTHESIS Other
"In Russia and Japan, outbreaks of Y pseudotuberculosis infection cause severe systemic inflammatory symptoms."
The review supports FESLF as a severe systemic branch of Y. pseudotuberculosis infection.
Izumi fever and Kawasaki-like mucocutaneous disease
Pediatric Y. pseudotuberculosis infection can clinically resemble Izumi fever and Kawasaki syndrome, with mucocutaneous inflammation, enteric symptoms, arthralgia, and hepatomegaly.
Show evidence (1 reference)
PMID:6344044 SUPPORT Human Clinical
"The patients' clinical manifestations and courses of illness resembled those of Izumi fever, an illness that occurs epidemically in Japan."
The 12-child clinical series explicitly relates Y. pseudotuberculosis infection to the Izumi fever syndrome.
🦠

Infectious Agent

1
Yersinia pseudotuberculosis
FESLF is caused by Far Eastern Y. pseudotuberculosis strains whose virulence program includes Yersinia pseudotuberculosis-derived mitogen A (YPMa), a T-cell superantigen implicated in the systemic inflammatory phenotype. The pVM82 plasmid is retained here as a reported clinical-epidemic strain marker; because the available review evidence does not distinguish a pVM82-encoded effector, the mechanistic pathograph follows YPMa.
Yersinia pseudotuberculosis NCBITaxon:633 NCBI Taxonomy (NCBITaxon)
Show evidence (2 references)
PMID:26819960 SUPPORT REVIEW SYNTHESIS Other
"Studies suggest the ability of Far Eastern strains to produce superantigen toxin Y pseudotuberculosis-derived mitogen A is integral to FESLF pathogenesis."
The FESLF review identifies Far Eastern YPMa-producing Y. pseudotuberculosis as the strain program that distinguishes this syndrome.
PMID:30695393 SUPPORT REVIEW SYNTHESIS Other
"pVM82 plasmid present only in Y pseudotuberculosis sttains causing clinical-epidemic manifestation of the infec- tions as Far East scarlet-like fever (FESLF)"
The plasmid-virulence review supports pVM82 as a marker reported in the Y. pseudotuberculosis strains that cause clinical-epidemic FESLF.
{ }

Source YAML

click to show 
name: Far-East Scarlet-Like Fever
creation_date: "2026-09-28T21:06:03Z"
category: Infectious Disease
description: >-
  Far-East scarlet-like fever is the severe Far Eastern systemic inflammatory
  form of Yersinia pseudotuberculosis infection, in which epidemic
  YPMa-superantigen-producing strains trigger Vbeta-restricted T-cell activation
  and a Kawasaki-like illness with fever, rash, desquamation,
  conjunctivitis, strawberry tongue, cheilitis, enteric symptoms, and arthralgia.
disease_term:
  preferred_term: Far-East scarlet-like fever
  term:
    id: MONDO:0041536
    label: Far-East scarlet-like fever
parents:
- Yersinia Pseudotuberculosis Infectious Disease
synonyms:
- FESLF
- Far East scarlet-like fever
- Izumi fever
infectious_agent:
- name: Yersinia pseudotuberculosis
  infectious_agent_term:
    preferred_term: Yersinia pseudotuberculosis
    term:
      id: NCBITaxon:633
      label: Yersinia pseudotuberculosis
  description: >-
    FESLF is caused by Far Eastern Y. pseudotuberculosis strains whose
    virulence program includes Yersinia pseudotuberculosis-derived mitogen A
    (YPMa), a T-cell superantigen implicated in the systemic inflammatory
    phenotype. The pVM82 plasmid is retained here as a reported
    clinical-epidemic strain marker; because the available review evidence does
    not distinguish a pVM82-encoded effector, the mechanistic pathograph follows
    YPMa.
  evidence:
  - reference: PMID:26819960
    reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Studies suggest the ability of Far Eastern strains to produce superantigen
      toxin Y pseudotuberculosis-derived mitogen A is integral to FESLF
      pathogenesis.
    explanation: >-
      The FESLF review identifies Far Eastern YPMa-producing Y.
      pseudotuberculosis as the strain program that distinguishes this syndrome.
  - reference: PMID:30695393
    reference_title: "[PLASMID-ASSOCIATED VIRULENCE OF YERSINIA PSEUDOTUBERCULOSIS AND INFECTIOUS PROCESS]."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      pVM82 plasmid present only in Y pseudotuberculosis sttains causing
      clinical-epidemic manifestation of the infec- tions as Far East
      scarlet-like fever (FESLF)
    explanation: >-
      The plasmid-virulence review supports pVM82 as a marker reported in the
      Y. pseudotuberculosis strains that cause clinical-epidemic FESLF.
definitions:
- name: Far-East scarlet-like fever syndrome
  definition_type: CASE_DEFINITION
  description: >-
    FESLF is the severe systemic inflammatory disease variant caused by Far
    Eastern Y. pseudotuberculosis strains, historically recognized in Russian
    Far East and Japanese outbreak settings as Izumi fever-like or
    Kawasaki-like pseudotuberculosis.
  evidence:
  - reference: PMID:26819960
    reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Far East scarlet-like fever (FESLF) is a severe inflammatory disease that
      occurs sporadically and in outbreaks in Russia and Japan.
    explanation: >-
      The review defines FESLF as the severe Far Eastern inflammatory disease
      variant of Y. pseudotuberculosis infection.
progression:
- phase: YPMa-positive systemic inflammatory yersiniosis
  notes: >-
    Far Eastern strains enter the superantigen-driven branch of Y.
    pseudotuberculosis infection rather than remaining a purely localized
    enteric illness.
  evidence:
  - reference: PMID:26819960
    reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      In Russia and Japan, outbreaks of Y pseudotuberculosis infection cause
      severe systemic inflammatory symptoms.
    explanation: >-
      The review supports FESLF as a severe systemic branch of Y.
      pseudotuberculosis infection.
- phase: Izumi fever and Kawasaki-like mucocutaneous disease
  notes: >-
    Pediatric Y. pseudotuberculosis infection can clinically resemble Izumi
    fever and Kawasaki syndrome, with mucocutaneous inflammation, enteric
    symptoms, arthralgia, and hepatomegaly.
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The patients' clinical manifestations and courses of illness resembled
      those of Izumi fever, an illness that occurs epidemically in Japan.
    explanation: >-
      The 12-child clinical series explicitly relates Y. pseudotuberculosis
      infection to the Izumi fever syndrome.
pathophysiology:
- name: Far Eastern YPMa Superantigen Production
  description: >-
    The defining bacterial input is a Far Eastern Y. pseudotuberculosis lineage
    that expresses the secreted YPMa superantigen, redirecting infection from
    localized gastroenteritis toward systemic FESLF inflammation.
  biological_scale: MOLECULAR
  downstream:
  - target: Superantigenic MHC-II and TCR Vbeta Engagement
    description: >-
      YPM engages MHC class II and T-cell receptor Vbeta surfaces rather than a
      conventional peptide-specific TCR groove.
    evidence:
    - reference: PMID:10406939
      reference_title: Analysis of functional regions of YPM, a superantigen derived from gram-negative bacteria.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        To study the mode of action of YPM at the molecular level, we first
        generated a number of YPM point mutants with reduced T-cell
        proliferative activity using random mutagenesis and localized the amino
        acid positions involved in either major histocompatibility complex class
        II or T-cell receptor Vbeta-interaction.
      explanation: >-
        Mutational analysis connects YPM-induced T-cell proliferation to
        residues involved in MHC class II and TCR Vbeta interaction.
  evidence:
  - reference: PMID:26819960
    reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Geographical heterogeneity exists between virulence factors produced by
      European and Far Eastern Y pseudotuberculosis strains, implicating
      superantigen Y pseudotuberculosis-derived mitogen A (YPMa) in the
      pathogenesis of FESLF.
    explanation: >-
      The review places YPMa specifically in the Far Eastern virulence program
      implicated in FESLF.
- name: Superantigenic MHC-II and TCR Vbeta Engagement
  description: >-
    YPM binds the Vbeta surface of T-cell receptors in a way that bypasses
    ordinary antigen specificity; point mutants defective in Vbeta binding show
    parallel attenuation of T-cell proliferation, cytotoxic activation, and
    proinflammatory cytokine release.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: T cell receptor signaling pathway
    term:
      id: GO:0050852
      label: T cell receptor signaling pathway
  downstream:
  - target: Vbeta-Restricted T Cell Activation
    description: >-
      TCR Vbeta binding converts the secreted bacterial mitogen into
      nonclonal, Vbeta-restricted T-cell stimulation.
    evidence:
    - reference: PMID:10087177
      reference_title: Generated single point-mutations can considerably dismantle the lymphocyte overstimulation induced by Yersinia pseudotuberculosis superantigen.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The SAg-associated in vitro pathogenic functions, cytotoxic activation
        and the production of proinflammatory cytokines, were also diminished,
        in parallel.
      explanation: >-
        The point-mutant study shows that mutations reducing YPM-driven T-cell
        proliferative responses also diminish superantigen-associated
        cytotoxic activation and proinflammatory cytokine production.
  evidence:
  - reference: PMID:10406939
    reference_title: Analysis of functional regions of YPM, a superantigen derived from gram-negative bacteria.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Finally, we obtained evidence that YPM partially competes with
      staphylococcal enterotoxin E for human leukocyte antigen-DR binding.
    explanation: >-
      In-vitro binding studies support HLA-DR engagement as part of the YPM
      superantigen mechanism.
- name: Vbeta-Restricted T Cell Activation
  description: >-
    In vivo exposure to YPM expands Vbeta-biased alpha-beta T cells; experimental
    YPM shock depends on CD4-positive, TCR Vbeta7/Vbeta8 T cells rather than on
    conventional antigen-specific T-cell priming.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T cell activation
    modifier: INCREASED
    term:
      id: GO:0042110
      label: T cell activation
  downstream:
  - target: YPM-Induced Proinflammatory Cytokine Production
    description: >-
      Activated Vbeta-restricted T cells drive TNF-alpha and IFN-gamma release,
      producing a shock-like inflammatory effector arm.
    evidence:
    - reference: PMID:9159409
      reference_title: Identification of murine T cells reactive with the bacterial superantigen Yersinia pseudotuberculosis-derived mitogen (YPM) and factors involved in YPM-induced toxicity in mice.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These results indicate that YPM-induced shock requires the presence of
        CD4+ T cells bearing TCR Vbeta7 and Vbeta8, and that endogenous
        TNF-alpha and IFN-gamma mediate the lethal effects.
      explanation: >-
        Antibody blockade in a mouse YPM shock model links CD4-positive
        Vbeta-restricted T cells to TNF-alpha and IFN-gamma-mediated systemic
        toxicity.
  - target: Superantigen-Activated T Cell Liver Homing
    description: >-
      YPM-activated Vbeta-biased T cells can rapidly traffic from blood into
      the liver in a superantigen shock model.
    evidence:
    - reference: PMID:15003813
      reference_title: Critical role of T cell migration in bacterial superantigen-mediated shock in mice.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We found that Vbeta8(+) T cells activated by YPM migrated from
        peripheral blood to liver as early as 1 h after injection of YPM
      explanation: >-
        The YPM mouse shock model provides a hepatic trafficking bridge between
        superantigen-activated T cells and liver enlargement reported in FESLF.
  evidence:
  - reference: PMID:9109426
    reference_title: Clinical role for a superantigen in Yersinia pseudotuberculosis infection.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      T cells bearing the Vbeta3 gene segment were significantly increased (P =
      0.009) among acute phase patients compared with healthy children.
    explanation: >-
      The human acute-infection series supports Vbeta-biased T-cell expansion
      during Y. pseudotuberculosis infection.
- name: YPM-Induced Proinflammatory Cytokine Production
  description: >-
    YPM-triggered T cells and peripheral blood leukocytes release
    proinflammatory cytokines, including TNF-alpha and interferon-gamma, forming
    a measured cellular effector response downstream of superantigenic T-cell
    activation.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: alpha-beta T cell
    term:
      id: CL:0000789
      label: alpha-beta T cell
  biological_processes:
  - preferred_term: cytokine production
    modifier: INCREASED
    term:
      id: GO:0001816
      label: cytokine production
  - preferred_term: type II interferon production
    modifier: INCREASED
    term:
      id: GO:0032609
      label: type II interferon production
  downstream:
  - target: FESLF Mucocutaneous and Systemic Inflammatory Syndrome
    description: >-
      YPM-triggered cytokine release is the superantigen effector arm that
      links Vbeta-restricted T-cell activation to the systemic FESLF syndrome.
    evidence:
    - reference: PMID:26819960
      reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
      supports: SUPPORT
      quote_role: REVIEW_SYNTHESIS
      evidence_source: OTHER
      snippet: >-
        Studies suggest the ability of Far Eastern strains to produce
        superantigen toxin Y pseudotuberculosis-derived mitogen A is integral to
        FESLF pathogenesis.
      explanation: >-
        The review connects the YPMa superantigen program to the systemic FESLF
        phenotype downstream of cytokine-producing T-cell activation.
    - reference: PMID:9159409
      reference_title: Identification of murine T cells reactive with the bacterial superantigen Yersinia pseudotuberculosis-derived mitogen (YPM) and factors involved in YPM-induced toxicity in mice.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These results indicate that YPM-induced shock requires the presence of
        CD4+ T cells bearing TCR Vbeta7 and Vbeta8, and that endogenous
        TNF-alpha and IFN-gamma mediate the lethal effects.
      explanation: >-
        The YPM shock model supports TNF-alpha and IFN-gamma as systemic
        mediators released downstream of Vbeta-biased CD4-positive T cells.
  evidence:
  - reference: PMID:15003813
    reference_title: Critical role of T cell migration in bacterial superantigen-mediated shock in mice.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We found that Vbeta8(+) T cells activated by YPM migrated from peripheral
      blood to liver as early as 1 h after injection of YPM and that serum level
      of IFN-gamma was significantly elevated 4 h after YPM injection.
    explanation: >-
      The mouse YPM shock model supports rapid Vbeta-biased T-cell activation
      followed by systemic IFN-gamma release.
  - reference: PMID:12449699
    reference_title: "[Impact of Yersinia pseudotuberculosis on the in vitro production of cytokines by whole blood cells of donors]."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The maximum stimulation of the production of cytokines was observed under
      the action of YPM, which confirmed an important role played by this
      superantigen in the pathogenesis of Y. pseudotuberculosis.
    explanation: >-
      Human whole-blood stimulation supports YPM as a potent cytokine-inducing
      superantigen.
- name: FESLF Mucocutaneous and Systemic Inflammatory Syndrome
  description: >-
    YPMa-positive systemic inflammation in children presents as an Izumi
    fever-like and Kawasaki-like syndrome with frequent fever, rash,
    mucocutaneous findings, gastrointestinal symptoms, arthralgia, and, in a
    Kawasaki-presenting subset, coronary artery lesions.
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Fever
    description: Fever belongs to the frequent systemic FESLF presentation.
  - target: Skin Rash
    description: Rash belongs to the frequent mucocutaneous FESLF presentation.
  - target: Diarrhea
    description: Diarrhea belongs to the frequent gastrointestinal FESLF presentation.
  - target: Desquamation
    description: Desquamation belongs to the frequent mucocutaneous FESLF presentation.
  - target: Strawberry Tongue
    description: Strawberry tongue belongs to the frequent oral mucosal FESLF presentation.
  - target: Vomiting
    description: Vomiting belongs to the frequent gastrointestinal FESLF presentation.
  - target: Red and Cracked Lips
    description: Cracked erythematous lips belong to the frequent oral mucosal FESLF presentation.
  - target: Abdominal Pain
    description: Abdominal pain belongs to the frequent gastrointestinal FESLF presentation.
  - target: Arthralgia
    description: Arthralgia belongs to the frequent systemic FESLF presentation.
  - target: Conjunctivitis
    description: Conjunctivitis belongs to the frequent mucocutaneous FESLF presentation.
  - target: Coronary Artery Lesions
    description: >-
      Kawasaki disease with evidence of Y. pseudotuberculosis infection has an
      enriched coronary artery lesion burden.
    evidence:
    - reference: PMID:17129979
      reference_title: Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the incidence of coronary artery lesions (dilatations plus aneurysms)
        in the Yersinia-positive group (22/42, 52.4%) was significantly higher
        than in the Yersinia-negative group (105/330, 31.8%) (p=0.001)
      explanation: >-
        The age-adjusted retrospective Kawasaki disease comparison links
        Yersinia-positive cases to a higher rate of coronary dilatations or
        aneurysms.
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally the finding in two children fulfilled the strict criteria
      for Kawasaki syndrome, and signs in the other 10 children were consistent
      with that diagnosis.
    explanation: >-
      The pediatric series documents that the common FESLF mucocutaneous and
      systemic findings clinically overlapped Kawasaki syndrome.
  - reference: PMID:26819960
    reference_title: "Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: >-
      Studies suggest the ability of Far Eastern strains to produce superantigen
      toxin Y pseudotuberculosis-derived mitogen A is integral to FESLF
      pathogenesis.
    explanation: >-
      Review-level evidence supports YPMa-driven superantigen inflammation as
      integral to the systemic FESLF syndrome.
- name: Superantigen-Activated T Cell Liver Homing
  description: >-
    YPM can recruit Vbeta-biased T cells into the liver in vivo, providing a
    model-organism bridge from the superantigenic T-cell node to the liver
    enlargement observed in pediatric FESLF.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: CD4-positive, alpha-beta T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  downstream:
  - target: Hepatomegaly
    description: >-
      Hepatic trafficking of YPM-activated T cells provides a plausible
      superantigen-linked bridge to hepatomegaly in FESLF.
    evidence:
    - reference: PMID:15003813
      reference_title: Critical role of T cell migration in bacterial superantigen-mediated shock in mice.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We found that Vbeta8(+) T cells activated by YPM migrated from
        peripheral blood to liver as early as 1 h after injection of YPM
      explanation: >-
        The mouse YPM shock model supports the hepatic T-cell trafficking step;
        the downstream hepatomegaly endpoint is anchored by the human pediatric
        case series.
  evidence:
  - reference: PMID:15003813
    reference_title: Critical role of T cell migration in bacterial superantigen-mediated shock in mice.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Vbeta8(+) T cells activated by YPM migrated from peripheral blood to liver
    explanation: >-
      The model directly measures YPM-activated Vbeta-biased T-cell migration
      into liver after superantigen exposure.
phenotypes:
- name: Fever
  description: >-
    Fever is part of the frequent pediatric FESLF/Izumi fever presentation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The 12-child clinical series found fever in at least half of patients with
      Y. pseudotuberculosis infection resembling Izumi fever and Kawasaki
      syndrome.
- name: Skin Rash
  description: >-
    Skin rash is one of the common mucocutaneous features in pediatric FESLF.
  phenotype_term:
    preferred_term: Skin rash
    term:
      id: HP:0000988
      label: Skin rash
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports rash among common findings in
      Y. pseudotuberculosis illness resembling Izumi fever.
- name: Diarrhea
  description: >-
    FESLF arises from enteric Y. pseudotuberculosis infection and commonly
    includes diarrhea.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series found diarrhea in at least half of Y.
      pseudotuberculosis patients with FESLF-like illness.
- name: Desquamation
  description: >-
    Scaling and peeling of the skin accompany the mucocutaneous inflammatory
    eruption.
  phenotype_term:
    preferred_term: desquamation
    term:
      id: HP:0040189
      label: Scaling skin
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports desquamation among the common mucocutaneous
      findings.
- name: Strawberry Tongue
  description: >-
    Strawberry tongue is part of the Kawasaki-like oral inflammatory phenotype
    in FESLF.
  phenotype_term:
    preferred_term: Strawberry tongue
    term:
      id: HP:0031042
      label: Strawberry tongue
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports strawberry tongue among common FESLF-like
      oral findings.
- name: Vomiting
  description: >-
    Vomiting can accompany the enteric phase of the systemic illness.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series found vomiting in at least half of patients.
- name: Red and Cracked Lips
  description: >-
    Cheilitis with red, cracked lips contributes to the Kawasaki-like oral
    mucosal phenotype.
  phenotype_term:
    preferred_term: red and cracked lips
    term:
      id: HP:0100825
      label: Cheilitis
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports red and cracked lips among common oral
      mucosal findings.
- name: Abdominal Pain
  description: >-
    Abdominal pain reflects the enteric and mesenteric component of Y.
    pseudotuberculosis infection in the systemic syndrome.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series found abdominal pain in at least half of patients.
- name: Arthralgia
  description: >-
    Joint pain commonly accompanies FESLF-like pediatric Y. pseudotuberculosis
    infection.
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports arthralgias among common findings.
- name: Hepatomegaly
  description: >-
    Liver enlargement can accompany the systemic inflammatory form of pediatric
    Y. pseudotuberculosis infection.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series found hepatomegaly in at least half of patients.
- name: Conjunctivitis
  description: >-
    Nonpurulent conjunctival inflammation is part of the Kawasaki-like
    mucocutaneous syndrome.
  phenotype_term:
    preferred_term: Conjunctivitis
    term:
      id: HP:0000509
      label: Conjunctivitis
  frequency: FREQUENT
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings in 50% or more of patients were fever, rash, diarrhea,
      desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal
      pain, arthralgias, hepatomegaly and conjunctivitis.
    explanation: >-
      The pediatric series reports conjunctivitis among common FESLF-like
      mucocutaneous findings.
- name: Coronary Artery Lesions
  description: >-
    Coronary artery dilatations or aneurysms are enriched in Kawasaki disease
    cases with elevated Y. pseudotuberculosis antibody titers or positive stool
    culture.
  phenotype_term:
    preferred_term: Coronary artery aneurysm
    term:
      id: HP:0030882
      label: Coronary artery aneurysm
  frequency: FREQUENT
  evidence:
  - reference: PMID:17129979
    reference_title: Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the incidence of coronary artery lesions (dilatations plus aneurysms) in
      the Yersinia-positive group (22/42, 52.4%) was significantly higher than
      in the Yersinia-negative group (105/330, 31.8%) (p=0.001)
    explanation: >-
      Coronary dilatations or aneurysms occurred in 52.4% of
      Yersinia-positive Kawasaki disease cases, supporting the FREQUENT band for
      Kawasaki-presenting FESLF.
diagnosis:
- name: Stool culture and paired agglutinating antibody titers
  description: >-
    Pediatric FESLF-like disease can be confirmed by recovering Y.
    pseudotuberculosis from stool and documenting a fourfold or greater change
    in agglutinating antibody titer; stool isolates may require cold enrichment.
  evidence:
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yersinia pseudotuberculosis infection was diagnosed in 12 children on the
      basis of recovery of the organism from stool cultures and a 4-fold or
      greater titer change in agglutinating antibody.
    explanation: >-
      The pediatric Izumi/Kawasaki-like series anchors stool culture and paired
      serology as confirmatory tests.
  - reference: PMID:6344044
    reference_title: Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight of the 12 Yersinia isolates were recovered from stool cultures only
      after cold enrichment.
    explanation: >-
      The same series documents that most stool isolates needed cold enrichment
      before recovery.
- name: Yersinia agglutination serology in refractory Kawasaki-like illness
  description: >-
    In Kawasaki-like presentations that persist despite immunomodulatory
    treatment, paired Yersinia agglutination titers can confirm infection even
    when blood and stool cultures are unrevealing.
  evidence:
  - reference: PMID:39697956
    reference_title: A Case of Refractory Kawasaki Disease With Yersinia pseudotuberculosis Infection Successfully Treated With Cefotaxime Following Immunosuppressive Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although stool and blood cultures did not detect any significant
      pathogens, analysis of Yersinia serum agglutinin titers revealed a result
      below detectable sensitivity on the second day of illness and a 640-fold
      increase on the 17th day.
    explanation: >-
      The Kawasaki-presenting case illustrates serologic confirmation after
      negative cultures.
treatments:
- name: Organism-directed antibiotic therapy
  description: >-
    Antibiotic therapy should be considered for severe, septicemic, or
    persistent Kawasaki-like Y. pseudotuberculosis disease once FESLF is
    suspected or confirmed.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: cefotaxime
      term:
        id: CHEBI:204928
        label: cefotaxime
    - preferred_term: imipenem
      term:
        id: CHEBI:471744
        label: imipenem
  evidence:
  - reference: PMID:39697956
    reference_title: A Case of Refractory Kawasaki Disease With Yersinia pseudotuberculosis Infection Successfully Treated With Cefotaxime Following Immunosuppressive Therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Based on these findings, cefotaxime was re-administered. The patient
      defervesced the next day and was afebrile late on with the improvement of
      inflammatory markers.
    explanation: >-
      The refractory Kawasaki-like pediatric case improved after cefotaxime was
      restarted for the underlying Y. pseudotuberculosis infection.
  - reference: PMID:18411766
    reference_title: "[Yersinia psuedotuberculosis septicemia in a healthy young woman]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After chemotherapy with imipenem, subjective symptoms ameliorated.
    explanation: >-
      This septicemic Y. pseudotuberculosis case supports antibiotic treatment
      for severe invasive disease.
- name: IVIG and aspirin for Kawasaki-presenting disease
  description: >-
    Kawasaki-presenting FESLF may require standard Kawasaki disease therapy with
    IVIG and aspirin to control vasculitis and limit coronary complications,
    while remaining alert to Yersinia-associated IVIG resistance.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: NCIT:C121331
      label: Intravenous Immunoglobulin Therapy
    therapeutic_agent:
    - preferred_term: Therapeutic Immune Globulin
      term:
        id: NCIT:C2701
        label: Therapeutic Immune Globulin
    - preferred_term: aspirin
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  evidence:
  - reference: PMID:17129979
    reference_title: Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the incidence of additional administration of immunoglobulin in the
      Yersinia-positive group (13/36, 36.1%) was significantly higher than in
      the Yersinia-negative group (41/256, 16.0%) (p=0.004).
    explanation: >-
      Yersinia-positive Kawasaki disease patients more often needed additional
      immunoglobulin, supporting IVIG relevance and resistance risk in this
      subset.
  - reference: PMID:39697956
    reference_title: A Case of Refractory Kawasaki Disease With Yersinia pseudotuberculosis Infection Successfully Treated With Cefotaxime Following Immunosuppressive Therapy.
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: OTHER
    snippet: >-
      Treatment includes intravenous immunoglobulin (IVIG) and aspirin to reduce
      complications, especially coronary artery issues.
    explanation: >-
      The Kawasaki/Yersinia case report restates IVIG plus aspirin as standard
      Kawasaki disease treatment for reducing coronary complications.
notes: >-
  Generic pYV-mediated adhesion, antiphagocytosis, and enteric invasion
  mechanisms remain inherited from the Yersinia pseudotuberculosis infectious
  disease parent. This child entry is restricted to the Far Eastern systemic
  branch centered on the YPMa superantigen and Kawasaki-like FESLF expression;
  postinfectious HLA-B27-associated reactive arthritis from European O:1/O:3
  Yersinia cohorts remains out of scope for this Far Eastern child entry.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Far-East Scarlet-Like Fever · 2026-09-29T00:26:03Z · View source

Created a focused Far-East Scarlet-Like Fever entry from OpenScientist deep research, verified FESLF was not already present on origin/main or in an open GitHub issue, curated the MONDO and Yersinia pseudotuberculosis bindings, added pVM82 as a Far Eastern strain marker, added a YPMa superantigen pathograph, added the pediatric Izumi fever/Kawasaki-like phenotype set from PMID:6344044, verified snippets and terms, and pruned uncited generated reference caches.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 45 citations 2026-09-28T14:27:55.479482

1. Disease Information

Overview. FESLF is a severe systemic inflammatory disease caused by Yersinia pseudotuberculosis. It represents the special "clinical-epidemic" manifestation of pseudotuberculosis that occurs sporadically and in outbreaks in Russia and Japan, in contrast to the milder self-limiting gastroenteritis seen in Europe (PMID: 26819960). A case series of 12 culture-confirmed children established the multisystem phenotype and noted that the illness "resembled those of Izumi fever, an illness that occurs epidemically in Japan" (PMID: 6344044).

Key identifiers.

Resource Identifier
MONDO MONDO:0041536
Causative organism (NCBI Taxonomy) Yersinia pseudotuberculosis, txid633
MeSH Yersinia pseudotuberculosis Infections (D015008)
ICD-10 A28.2 (Extraintestinal yersiniosis) / A04.8
OMIM Not applicable (non-genetic, infectious disease)
Orphanet Not a listed rare Mendelian disease

Synonyms / alternative names. Far East scarlet-like fever; Far Eastern scarlet-like fever; Izumi fever (Japan); Far-Eastern scarlatiniform fever; a clinical-epidemic form of pseudotuberculosis / extraintestinal yersiniosis. The relation to Izumi fever and Kawasaki disease is explicitly established in the literature (PMID: 6344044; PMID: 39780644).

Source of information. The knowledge base is derived from aggregated disease-level resources — case series, outbreak investigations, genomic/phylogenetic studies, and mechanistic in vitro/animal experiments — rather than individual EHR-derived patient records.

2. Etiology

Disease causal factors. FESLF is caused by infection with Y. pseudotuberculosis, specifically Far-Eastern "Asian clade" strains carrying the superantigen gene ypmA and (in clinical-epidemic strains) the pVM82 plasmid (PMID: 26819960; PMID: 30695393; PMID: 39780644). The disease is fundamentally toxin-mediated: the YPM superantigen drives the systemic manifestations.

Environmental risk factors. Transmission is foodborne/waterborne; documented vehicles include contaminated grated carrots (PMID: 23852698) and other fresh produce and water. The organism is psychrotrophic (grows at refrigeration temperatures), enabling amplification in stored vegetables. Age is a risk modifier — the underlying infection disproportionately affects children, and Yersinia-associated KD occurs at older onset age (3.05 ± 2.20 y vs 2.31 ± 2.05 y; p = 0.03) (PMID: 17129979). Immunocompromise and iron overload predispose to invasive/septicemic disease (PMID: 42448289).

Genetic (host) risk factors. Host genetics do not cause FESLF but modify post-infectious complications: HLA-B27 strongly predisposes to reactive arthritis after Y. pseudotuberculosis infection (PMID: 23852698; PMID: 12922960). The TCR Vβ repertoire of the host (Vβ3/9/13.1/13.2) determines which T cells respond to YPM. NOD2 and ATG16L1 autophagy polymorphisms have been implicated in susceptibility to Yersinia mucosal disease in the IBD context (PMID: 42661478).

Protective factors. No germline protective alleles are established for FESLF itself. Antibiotic therapy and prior immunity (anti-YPM antibodies) modulate course. Food-hygiene behaviors are the principal protective/preventive measures.

Gene–environment interactions. The defining interaction is between the bacterial superantigen (environmental/infectious agent) and the host MHC-II/TCR-Vβ genotype: the same toxin produces variable illness depending on host HLA-DR and Vβ repertoire. Separately, HLA-B27 × Yersinia infection markedly raises reactive-arthritis risk — a classic gene–environment interaction.

3. Phenotypes

The core phenotype was quantified in a case series of 12 children with culture-confirmed Y. pseudotuberculosis (stool culture plus ≥4-fold agglutinating-antibody rise); clinical findings present in ≥50% of patients are listed below (PMID: 6344044).

Phenotype Type Frequency (≥50% cohort) Suggested HPO term
Fever Symptom ≥50% HP:0001945
Scarlatiniform rash Skin sign ≥50% HP:0000988 (Skin rash)
Diarrhea Symptom ≥50% HP:0002014
Desquamation Skin sign ≥50% HP:0007556 (Palmoplantar desquamation)
Strawberry tongue Sign ≥50% HP:0000206 (Glossitis, related)
Vomiting Symptom ≥50% HP:0002013
Red, cracked lips Sign ≥50% HP:0000202 (Oral cavity abnormality)
Abdominal pain Symptom ≥50% HP:0002027
Arthralgias Symptom ≥50% HP:0002829
Hepatomegaly Sign ≥50% HP:0002240
Conjunctivitis Sign ≥50% HP:0000509

Direct quote: "Clinical findings in 50% or more of patients were fever, rash, diarrhea, desquamation, strawberry tongue, vomiting, red and cracked lips, abdominal pain, arthralgias, hepatomegaly and conjunctivitis" (PMID: 6344044).

Additional phenotypes documented in adults/severe cases: membranous fingertip/interdigital desquamation (PMID: 42778384; PMID: 18411766), hepatic dysfunction and elevated inflammatory markers, erythema nodosum (42% of children in one carrot-borne outbreak), and reactive arthritis. Laboratory abnormalities include leukocytosis, elevated CRP/ferritin, and in severe cases thrombocytopenia with DIC (PMID: 16366361).

Onset/severity/progression. Onset is acute (childhood-predominant). Severity ranges mild to severe; most cases are self-limited over days to weeks, but a subset progresses to systemic toxicity, coronary involvement (KD-like), DIC, or septicemia. Reactive arthritis can become chronic (>6 months) and rarely fatal (secondary amyloidosis).

Quality-of-life impact. Acute illness impairs feeding, activity, and school attendance. Chronic reactive arthritis and ankylosing spondylitis produce sustained functional disability; fatal amyloidosis with uremia has been reported in long-term follow-up (PMID: 7554560).

4. Genetic / Molecular Information

FESLF is not a human genetic disease — there are no causal human genes, pathogenic germline variants, or chromosomal abnormalities. The relevant "genetics" are those of the pathogen and of host susceptibility loci.

Pathogen virulence genes.

Determinant Function Association with FESLF
ypmA (encodes YPMa) Superantigen mitogen Present in 96.2% of Far-Eastern strains; hallmark of systemic disease (PMID: 17163133)
ypmB, ypmC Superantigen variants ypmB Far-East-restricted cluster B; ypmC rare (PMID: 21131531)
pVM82 (82-MDa) plasmid Uncharacterized virulence Present only in clinical-epidemic FESLF strains (PMID: 30695393)
pYV virulence plasmid (virF) Type III secretion system / Yops Universal in pathogenic strains (PMID: 18242014)
inv (invasin) β1-integrin adhesion, M-cell invasion Universal; mediates epithelial crossing (PMID: 25576025)
HPI / irp2 High-pathogenicity island (iron uptake) Absent in dominant FESLF genogroup (PMID: 17163133)
pil (type IV pilus) Adhesion Co-acquired with ypm horizontally (PMID: 15784605)

The dominant systemic-infection genogroup is pYV⁺ / ypmA⁺ / HPI⁻ (95.8% of Siberian/Far-Eastern strains) (PMID: 17163133). The ypm and pil genes were laterally (horizontally) acquired and are significantly co-associated (PMID: 15784605).

Host susceptibility loci. HLA-B27 (reactive arthritis modifier); HLA-DR (YPM presentation); TCR Vβ genes BV3S1, BV9, BV13 (target of YPM); C4B copy number (modifies Yersinia-microbiota interaction in pediatric IBD) (PMID: 28832994).

Epigenetics. No disease-specific human epigenetic signature is established for FESLF. Superantigen-driven T-cell activation induces transcriptional/epigenetic reprogramming toward effector/memory phenotypes (PMID: 11937534), but this is not disease-defining.

5. Environmental Information

Infectious agent. Yersinia pseudotuberculosis (family Yersiniaceae; NCBI Taxonomy txid633), a Gram-negative, psychrotrophic, facultatively anaerobic coccobacillus. Serotypes O:1 (incl. Ib) and O:3 are the principal causes of documented outbreaks and post-infectious complications; serotypes 4b and 1b predominate in fatal Japanese monkey outbreaks (PMID: 18242014).

Environmental factors. The organism is widespread in the terrestrial environment and can persist in soil and water, in wildlife reservoirs (rodents, wild boars, birds), and even the marine habitat (PMID: 42431144; PMID: 29980552). Its cold tolerance allows growth in refrigerated foods.

Lifestyle factors. Consumption of raw or improperly washed vegetables (carrots, lettuce) and untreated water; contact with animal reservoirs. Outbreaks are typically food/water-associated. The dominant environmental "cause" is ingestion of contaminated food, then M-cell invasion in the terminal ileum.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. Ingestion of Y. pseudotuberculosis (Asian-clade, ypmA⁺, pVM82⁺) in contaminated food/water → leads to delivery of viable bacteria to the terminal ileum.
  2. Bacterial invasin binds host β1-integrins on M cells of Peyer's patches → results in translocation across the intestinal epithelium (PMID: 25576025).
  3. Bacteria reach the mesenteric lymph nodes, liver, and spleen; the type III secretion system (pYV/Yops) is selectively translocated into professional phagocytes (neutrophils, macrophages, dendritic cells), disarming innate clearance → leads to local persistence and granulomatous terminal ileitis / mesenteric lymphadenitis (PMID: 20148898; PMID: 34628159).
  4. The bacterium secretes/expresses the superantigen YPMa → which binds MHC class II (HLA-DR) on antigen-presenting cells outside the conventional peptide groove (PMID: 10406939).
  5. The MHC-II–YPM complex cross-links T-cell receptors bearing Vβ3, 9, 13.1, 13.2 → results in massive polyclonal (Vβ-restricted) T-cell activation (PMID: 9287138; PMID: 17369701).
  6. Activated Vβ⁺ T cells migrate from blood to liver within 1 h and release a cytokine storm (IFN-γ by 4 h, plus TNF-α, IL-1, IL-6, IFN-α) → leads to systemic inflammation, hepatic injury, and toxic shock (PMID: 15003813; PMID: 12449699).
  7. Systemic cytokine excess and vascular inflammation produce the clinical syndrome: fever, scarlatiniform rash, desquamation, strawberry tongue, conjunctivitis, hepatomegaly → the FESLF/Kawasaki-like phenotype.
  8. Branch A (severity): the intensity of TCR-Vβ binding scales the magnitude of T-cell overstimulation, cytotoxicity, and cytokine output → determines disease severity (PMID: 10087177).
  9. Branch B (cardiac): in a subset, superantigen-driven vasculitis → coronary artery dilation/aneurysm (Kawasaki-disease phenotype), with higher coronary-lesion rates and IVIG resistance in Yersinia-associated KD (PMID: 17129979).
  10. Branch C (post-infectious autoimmunity): in HLA-B27⁺ hosts, molecular/immune cross-reactivity → reactive arthritis, ankylosing spondylitis, erythema nodosum, rarely secondary amyloidosis (PMID: 23852698; PMID: 7554560).

Detail by category

  • Molecular pathways: TCR/CD3 → ZAP-70 → PLCγ/PKC/NF-κB and Ras-MAPK signaling driving IL-2/IFN-γ transcription (superantigen-driven); β1-integrin → PI3K signaling in invasin-mediated neutrophil activation and NET formation (PMID: 25576025); RhoG/Rac1 GTPase modulation by invasin/Yops during invasion (PMID: 19208761).
  • Cellular processes: massive T-cell proliferation and later anergy/deletion; macrophage/DC activation; neutrophil extracellular trap (NET) release; inflammasome activation and pyroptosis in Yersinia mucosal disease (PMID: 42661478); granuloma formation.
  • Protein dysfunction (toxin structure): YPMa is a ~150-aa protein adopting a jelly-roll fold resembling viral capsid/TNF-superfamily proteins, with no sequence homology to other superantigens; crystallized in space group C2, 1.8 Å resolution; an internal disulfide (S–S) bond is essential for activity (PMID: 12832802; PMID: 17369701; PMID: 10406939).
  • Immune system involvement: superantigen-mediated polyclonal T-cell activation, IFN-γ–dominated cytokine storm; T-cell-dependent toxicity (toxic shock in BALB/c but not T-cell-deficient SCID mice) (PMID: 15003813).
  • Tissue damage mechanisms: IFN-γ/TNF-α–mediated hepatocellular injury; immune-complex and vasculitic damage to coronary vessels; granulomatous necrosis in ileum/lymph nodes.
  • Suggested GO terms: GO:0042110 (T cell activation), GO:0032609 (interferon-gamma production), GO:0050852 (T cell receptor signaling pathway), GO:0006955 (immune response), GO:0002250 (adaptive immune response), GO:0001816 (cytokine production).
  • Suggested CL terms: CL:0000624 (CD4⁺ T cell), CL:0000625 (CD8⁺ T cell), CL:0000775 (neutrophil), CL:0000235 (macrophage), CL:0000451 (dendritic cell), CL:0000794 (CD8⁺ cytotoxic T cell).

7. Anatomical Structures Affected

Organ level. - Primary: terminal ileum (UBERON:0002116), mesenteric lymph nodes (UBERON:0002509), liver (UBERON:0002107). - Secondary/systemic: skin (UBERON:0002097), oral mucosa/tongue (UBERON:0001723), conjunctiva (UBERON:0001811), coronary arteries (UBERON:0001621) in KD-like cases, joints/synovium (UBERON:0002217) in reactive arthritis, spleen (UBERON:0002106), pancreas (UBERON:0001264; Yersinia pancreatitis, PMID: 22416431). - Body systems: digestive, lymphatic/immune, integumentary, cardiovascular, musculoskeletal, hepatobiliary.

Tissue/cell level. Intestinal epithelium (M cells), lymphoid tissue (Peyer's patches, UBERON:0001211), vascular endothelium (coronary artery endothelial cells), synovium. Cell populations: CD4⁺/CD8⁺ T cells (Vβ3/9/13⁺), professional phagocytes, epithelioid histiocytes forming granulomas with giant cells.

Subcellular level. T-cell plasma membrane (TCR–MHC-II synapse); cytokine secretory machinery (ER/Golgi). Suggested GO cellular-component terms: GO:0009897 (external side of plasma membrane), GO:0042101 (T cell receptor complex), GO:0042613 (MHC class II protein complex).

Localization/lateralization. Terminal ileitis is typically right-lower-quadrant, mimicking appendicitis; coronary lesions may be bilateral; reactive arthritis is often asymmetric oligoarticular (lower limbs) but can be polyarticular (PMID: 12922960).

8. Temporal Development

Onset. Acute, pediatric-predominant; incubation typically a few days to ~2 weeks after ingestion. In the case series the illness was acute and multisystem (PMID: 6344044).

Progression and course. Most acute illness is self-limited over 1–3 weeks. A minority progress to systemic toxicity (toxic-shock-like), DIC (PMID: 16366361), coronary involvement, or septicemia (higher risk in immunocompromised/iron-overloaded hosts, PMID: 42448289). Post-infectious reactive arthritis appears days to weeks after the acute phase and may persist >6 months in a substantial fraction; a 10-year follow-up found chronic joint symptoms in 9/16 patients including ankylosing spondylitis and fatal secondary amyloidosis (PMID: 7554560).

Patterns. Acute phase resolves spontaneously or with antibiotics; complications may be relapsing (reactive arthritis reactivation) or progressive (spondyloarthropathy/amyloidosis). The critical intervention window for KD-like cases is the first ~10 days (IVIG to prevent coronary aneurysm).

9. Inheritance and Population

Inheritance. None — FESLF is infectious, not heritable. No Mendelian inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity, or carrier frequency applies to the disease itself. (Host modifiers such as HLA-B27 follow their own inheritance but only affect complication risk.)

Epidemiology and geography. FESLF is geographically restricted to the Russian Far East, Siberia, and Japan, occurring sporadically and in outbreaks (PMID: 26819960; PMID: 32498317). This restriction tracks the geographic distribution of ypmA⁺ Asian-clade strains: ypmA detected in 96.2% of 212 Siberian/Far-Eastern strains (PMID: 17163133) and 88.9% of fatal Japanese monkey-outbreak strains (PMID: 18242014). By contrast, European Y. pseudotuberculosis infection is sporadic self-limiting gastroenteritis (PMID: 26819960). General yersiniosis incidence in non-endemic regions is low (e.g., ~0.16/100,000/yr in a multistate US study; Y. pseudotuberculosis is a small minority of cases) (PMID: 25931631; PMID: 26233079).

Demographics. Children are predominantly affected; Yersinia-associated KD onset is older than Yersinia-negative KD (3.05 vs 2.31 y; p = 0.03) (PMID: 17129979). Sex ratio is not strongly skewed for the acute disease; HLA-B27-associated reactive arthritis affects both sexes.

Population structure of the pathogen. MLST reveals a worldwide cluster A (ypmA, pYV) and a Far-East-restricted cluster B (ypmB); the ypm superantigen genes are distributed across the phylogeny with ypmA in cluster A and ypmB in cluster B (PMID: 21131531). FESLF strains belong to the Asian clade and are KD-related (PMID: 39780644).

10. Diagnostics

Microbiology. Stool culture and/or blood culture for Y. pseudotuberculosis (cold enrichment improves yield); serotyping (O:1, O:3, 4b). Blood culture positivity in septicemic cases (PMID: 18411766).

Serology. ≥4-fold rise in agglutinating antibody titers is diagnostic (PMID: 6344044); tube agglutination titers (e.g., ≥1:160 against serotype 4b) support diagnosis (PMID: 18411766). Anti-YPM (anti-mitogen) antibody titers rise between days 7–18 and confirm infection when cultures are negative (PMID: 34108299; PMID: 16366361). Serology is described as the most informative laboratory approach (PMID: 22416431).

Molecular. PCR for virulence genes — ypm (ypmA/B/C), virF, inv, irp2 — enables genotype-based confirmation and epidemiologic typing (PMID: 18242014; PMID: 22416431).

Laboratory abnormalities. Leukocytosis, elevated CRP/ferritin, transaminase elevation (hepatic involvement), thrombocytopenia and prolonged PT/PTT with elevated FDP in DIC (PMID: 16366361).

Imaging/histopathology. Ultrasound/CT show mesenteric lymphadenopathy and terminal ileitis; echocardiography detects coronary dilation/aneurysm in KD-like cases. Biopsy shows epithelioid granulomas with reticular microabscesses/stellate necrosis and giant cells, mimicking Crohn's disease (PMID: 22228001; PMID: 18368812; PMID: 26385573).

Clinical criteria / differential diagnosis. When patients meet Kawasaki-disease criteria (fever ≥5 days plus ≥4 of: rash, conjunctivitis, oral changes, extremity changes, cervical lymphadenopathy), Y. pseudotuberculosis should be excluded (PMID: 39697956). Differentials: scarlet fever (Group A Streptococcus), Kawasaki disease, appendicitis, Crohn's disease, mesenteric adenitis of other cause, other yersiniosis. Genetic testing is not applicable (no germline cause).

11. Outcome / Prognosis

Survival/mortality. The acute disease is usually self-limited with low mortality when treated. Severe outcomes include septicemia with multi-organ dysfunction (fatal cases reported, especially in immunocompromised/iron-overload hosts, PMID: 42448289) and DIC (PMID: 16366361). Long-term fatal outcomes are rare and usually via reactive-arthritis complications (secondary amyloidosis → uremia) (PMID: 7554560).

Morbidity/complications. Coronary artery lesions (KD phenotype): significantly more frequent in Yersinia-positive KD (22/42, 52.4%) than Yersinia-negative KD (105/330, 31.8%; p = 0.001), with greater need for additional IVIG (36.1% vs 16.0%; p = 0.004) (PMID: 17129979). Post-infectious reactive arthritis in 12–22% of adults, HLA-B27-associated, sometimes chronic/polyarticular (PMID: 23852698; PMID: 12922960); erythema nodosum (42% of children in one outbreak); rarely ankylosing spondylitis and amyloidosis.

Prognostic factors. Presence of ypmA⁺ Far-Eastern strain and pVM82 plasmid (severity); host HLA-B27 (reactive-arthritis risk); older age and Yersinia positivity (coronary-lesion risk and IVIG resistance in KD); immunocompromise/iron overload (septicemia risk). Anti-YPM antibody serology serves as a diagnostic/prognostic biomarker.

12. Treatment

Pharmacotherapy (antibiotics). Y. pseudotuberculosis is generally susceptible to third-generation cephalosporins (cefotaxime, ceftriaxone), fluoroquinolones, aminoglycosides, tetracyclines, and trimethoprim-sulfamethoxazole; carbapenems (imipenem) used in severe/septicemic disease (PMID: 18411766). Refractory KD-presenting cases have responded to cefotaxime after immunosuppressive therapy (PMID: 39697956). Suggested NCIT: C264 (Cephalosporin), C540 (Ciprofloxacin), C61796 (Cefotaxime).

Kawasaki-disease-presenting cases. Intravenous immunoglobulin (IVIG) plus aspirin to reduce coronary complications; note higher IVIG-resistance in Yersinia-associated KD, sometimes requiring additional IVIG or immunosuppression (PMID: 17129979; PMID: 39697956). NCIT: C488 (Immunoglobulin therapy), C287 (Aspirin).

Reactive arthritis. NSAIDs, and in chronic/severe spondyloarthropathy, DMARDs; supportive rheumatologic care.

Supportive care. Fluid/electrolyte management for diarrhea/vomiting; DIC management; hepatic monitoring.

Advanced/experimental therapeutics. A conceptual therapeutic avenue arises from mutagenesis work: engineered YPM point mutants with reduced TCR-Vβ binding lose overstimulatory/cytotoxic activity and could serve as immunotherapeutic/vaccine antigens (PMID: 10087177). Anti-IFN-γ and anti-YPM antibodies prevented liver injury and death in mice — a proof-of-concept for toxin/cytokine-neutralizing therapy (PMID: 15003813). No approved gene, cell, or RNA therapy exists or is applicable.

Pharmacogenomics. Not established for FESLF.

13. Prevention

Primary prevention. Food and water hygiene: thorough washing of raw vegetables (carrots, leafy greens), safe water, cold-chain awareness (organism grows at refrigeration temperatures). Outbreak control through tracing contaminated produce (PMID: 23852698).

Immunization. No licensed human vaccine against Y. pseudotuberculosis/FESLF. An attenuated Y. pseudotuberculosis strain (lacking HPI, ypm, pil; retaining pYV) has been used experimentally as an oral live vaccine against plague, protecting 75–88% of mice — illustrating vaccine-platform potential but not a FESLF vaccine (PMID: 18505804).

Secondary/tertiary prevention. Early antibiotic treatment; early echocardiography and IVIG in KD-presenting cases to prevent coronary aneurysm; monitoring/treatment of reactive arthritis to prevent chronic sequelae.

Public health. Surveillance of foodborne yersiniosis; produce-supply monitoring; reservoir awareness (rodents, wild boars, birds). Vector control is not relevant (foodborne, not vector-borne).

14. Other Species / Natural Disease

Taxonomy of causative agent. Yersinia pseudotuberculosis (NCBI:txid633).

Natural disease in animals. Pseudotuberculosis is a common cause of mortality in captive exotic birds and mammals; per OIE WAHIS-Wild it is the 8th most frequently reported disease/infection in wildlife worldwide and 5th in wild mammals (PMID: 42431144). Fatal outbreaks in breeding monkeys in Japanese zoos (28 deaths, 8 species; 88.9% ypmA⁺) directly parallel human FESLF and implicate YPM in high mortality (PMID: 18242014). Documented in wild boars (PMID: 29980552) and, newly, free-ranging marine odontocetes (PMID: 42431144).

Zoonotic potential / reservoirs. Rodents, birds, and other mammals serve as reservoirs; transmission to humans is principally by ingestion of contaminated food or water. Cross-species susceptibility is broad.

Comparative biology. The superantigen mechanism is conserved: ypmA⁺ strains cause severe/fatal systemic disease across primates and humans, supporting evolutionary conservation of the YPM–MHC-II/TCR-Vβ axis.

15. Model Organisms

Mouse models. BALB/c mice develop YPM-induced toxic shock; T-cell-deficient SCID mice do not, establishing T-cell dependence (PMID: 15003813). Mini-osmotic-pump delivery of YPM produces protracted Vβ3⁺CD4⁺ T-cell expansion and immunological memory, modeling chronic superantigen exposure (PMID: 11937534). A murine coronary-arteritis (KD) model is induced by oral microbe-associated molecular patterns, linking Yersinia biofilm MAMPs to KD-like vasculitis (PMID: 25411968).

Rat models. HLA-B27 transgenic rats mount a CD8⁺ CTL response to Y. pseudotuberculosis; HLA-B27 exerts a negative effect on this response, modeling impaired defense and the HLA-B27–reactive-arthritis link (PMID: 10417137). LEW rat BV8S2⁺ T cells respond to YPM, used to map TCR CDR/HV4 contributions to superantigen recognition (PMID: 15096488).

Non-human primates. Naturally infected breeding monkeys constitute a spontaneous high-fidelity model of fatal systemic ypmA⁺ disease (PMID: 18242014).

In vitro / structural. Human whole-blood cytokine assays (YPM elicits maximal IL-1/IL-6/IFN-α/TNF-α, PMID: 12449699); recombinant YPM mutagenesis systems for structure–function (PMID: 10406939; PMID: 10087177); X-ray crystallography/NMR of YPMa (PMID: 12832802; PMID: 17369701).

Recapitulation/limitations. Mouse models capture superantigen-driven T-cell activation and toxic shock but incompletely reproduce the full mucosal→systemic human sequence; the HLA-B27 rat captures the reactive-arthritis modifier but not the acute scarlatiniform phenotype.

Mechanistic Model / Interpretation

 CONTAMINATED FOOD/WATER (ypmA+, pVM82+, pYV+ Asian-clade Y. pseudotuberculosis)
│  ingestion
▼
 TERMINAL ILEUM ── invasin·β1-integrin ──► M-cell translocation (Peyer's patches)
│
▼
 MESENTERIC LYMPH NODES / LIVER / SPLEEN
│  T3SS(Yops)→phagocytes: immune evasion + granulomatous ileitis/adenitis
│  (Crohn's-mimicking target lesion)
▼
 YPMa SUPERANTIGEN ── binds HLA-DR (MHC-II) + TCR Vβ3/9/13.1/13.2 ──►
│  polyclonal, Vβ-restricted T-cell activation
▼
 CYTOKINE STORM (IFN-γ @4h, TNF-α, IL-1, IL-6, IFN-α)   ── T-cell-dependent
│                                                  (absent in SCID mice)
├──────────────► SYSTEMIC ILLNESS: fever, scarlatiniform rash,
│                desquamation, strawberry tongue, conjunctivitis,
│                hepatomegaly  =  FESLF / Izumi fever
│
├── Branch A (dose/affinity): TCR-Vβ binding intensity → SEVERITY
│
├── Branch B: coronary vasculitis → KD phenotype (↑coronary lesions,
│              IVIG resistance)
│
└── Branch C (HLA-B27+ host): post-infectious reactive arthritis,
               ankylosing spondylitis, erythema nodosum, amyloidosis

The unifying interpretation is that FESLF is fundamentally a superantigen toxicosis superimposed on an enteric invasive infection. What distinguishes the Far-Eastern severe disease from European mild yersiniosis is not the route or the organism per se but the horizontally acquired ypmA superantigen (plus the enigmatic pVM82 plasmid). Severity is a graded function of TCR-Vβ engagement, and the host HLA background (HLA-DR for presentation, HLA-B27 for post-infectious autoimmunity) shapes both acute magnitude and chronic sequelae. This model explains the disease's geographic restriction, its overlap with scarlet fever and Kawasaki disease, and the rationale for both antibiotic (source control) and immunomodulatory (IVIG/anti-cytokine) treatment.

Evidence Base

PMID Contribution
6344044 Defines the multisystem scarlet-fever/KD-like phenotype; links to Izumi fever (12-child series)
39780644 FESLF strains = Asian clade, KD-related (genomics)
26819960 Review: FESLF definition, Russia/Japan geography, YPMa role
30695393 pVM82 plasmid unique to FESLF clinical-epidemic strains
17163133 ypmA in 96.2% of Far-Eastern strains; pYV⁺/ypmA⁺/HPI⁻ systemic genogroup
18242014 88.9% ypmA⁺ in fatal Japanese monkey outbreaks
15784605 Horizontal acquisition/linkage of ypm and pil
21131531 Population structure: cluster A (ypmA) worldwide, cluster B (ypmB) Far-East
15003813 T-cell-dependent YPM toxicity; Vβ8⁺ migration to liver; IFN-γ surge; antibody protection
12449699 YPM = maximal cytokine inducer among Yersinia stimuli
12832802 YPM crystallization; no homology to other superantigens
17369701 Jelly-roll fold of YPMa; YPMa/b/c family
10406939 YPM competes with SEE for HLA-DR; MHC-II/TCR mapping; essential S–S bond
9287138 YPMb shares Vβ3/9/13.1/13.2 specificity
10087177 TCR-Vβ binding intensity determines pathogenic severity
17129979 Yersinia-KD: ↑coronary lesions (52.4% vs 31.8%, p=0.001), IVIG resistance
34108299 Anti-YPM antibody serology confirms infection; intussusception + incomplete KD
16366361 KD-criteria case with DIC; anti-YPM serology
39697956 Refractory KD with Y. pseudotuberculosis treated with cefotaxime
10592892 Superantigen hypothesis for KD pathogenesis
23852698 O:1 carrot outbreak: ReA 22% adults, 67% HLA-B27⁺, EN 42% children
12922960 O:3 outbreak: severe polyarticular ReA, HLA-B27⁺
7554560 10-yr follow-up: chronic arthritis, ankylosing spondylitis, fatal amyloidosis
34628159 Meta-analysis: Yersinia 65% terminal ileitis, 51% mesenteric adenitis
22228001 Terminal ileitis mimicking Crohn's in childhood
18368812 Granulomatous Yersinia pathology resembling Crohn's
26385573 Histopathologic IBD mimics incl. Yersinia
25576025 Invasin·β1-integrin → NETs (innate arm)
20148898 T3SS Yop translocation selectively to phagocytes
18505804 Attenuated Y. pseudotuberculosis oral vaccine concept
10417137 HLA-B27 transgenic rat CTL model
42448289 Fatal septicemia in immunocompromised/iron-overload host

Limitations and Knowledge Gaps

  1. No dedicated primary data were analyzed — this is a literature synthesis. Some key sources are non-English (Russian/Japanese) with abstracts unavailable, limiting extraction of quantitative detail (e.g., precise FESLF incidence/prevalence per 100,000, which remains unquantified in the accessible literature).
  2. pVM82 plasmid biology is understudied — it is a molecular marker of FESLF strains, but its gene content and mechanistic contribution to severity are essentially uncharacterized (PMID: 30695393).
  3. Direct in vivo demonstration that YPMa alone reproduces the full FESLF rash/desquamation phenotype is lacking — most mechanistic data derive from toxic-shock and cytokine models rather than the complete syndrome.
  4. Causality vs. association in Kawasaki disease — the Yersinia–KD link is strong epidemiologically and serologically, but whether Y. pseudotuberculosis is a cause of a KD subset or a mimicker remains debated.
  5. Epidemiologic underreporting — yersiniosis is under-diagnosed and under-serotyped even in surveillance systems (PMID: 26233079), so true FESLF burden in endemic regions is uncertain.
  6. No modern randomized treatment trials — antibiotic and IVIG recommendations rest on case series and analogy to KD, not RCTs.

Proposed Follow-up Experiments / Actions

  1. Sequence and functionally annotate the pVM82 plasmid across FESLF vs non-FESLF strains (comparative genomics + isogenic cured-plasmid virulence assays) to test whether pVM82 independently contributes to severity beyond ypmA.
  2. Isogenic ΔypmA vs ypmA⁺ challenge in a humanized-HLA-DR/Vβ mouse or primate model to formally establish YPMa's necessity/sufficiency for the FESLF phenotype.
  3. Prospective serologic cohort of KD patients in endemic vs non-endemic regions using standardized anti-YPM assays to quantify the attributable fraction of Yersinia-associated KD and its coronary-outcome risk.
  4. Structure-guided anti-YPM therapeutics: develop neutralizing monoclonal antibodies or engineered Vβ-decoy proteins based on the jelly-roll fold and the demonstrated protection by anti-YPM/anti-IFN-γ antibodies (PMID: 15003813).
  5. HLA-B27 stratified natural-history study to define reactive-arthritis and amyloidosis risk after Y. pseudotuberculosis infection and guide surveillance.
  6. Regional epidemiologic quantification in the Russian Far East/Japan to populate incidence/prevalence fields (currently unfilled) and map ypmA/pVM82 genotype distribution to case severity.
  7. Update ontology mappings for the knowledge base: confirm MONDO:0041536 cross-references to MeSH/ICD, and attach the HPO, GO, CL, UBERON, and NCIT terms proposed in Sections 3–12.

Report compiled from 65 reviewed papers and 8 confirmed findings over a 5-iteration autonomous investigation. Evidence types: human clinical (case series, outbreaks, cohorts), model organism (mouse, rat, primate), in vitro (cytokine assays, mutagenesis), and structural/computational (X-ray crystallography, NMR, genomics).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 46
Resolved 46
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 1
Quoted claims not found in source 0
References weighed for topical relevance 46
On topic 15
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 38
Resolved 38
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 22
Terms named correctly 12
Terms named as a different term 2
Terms whose name is worth a second look 8

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0041536 (3 mentions) - the report calls it "MONDO"; MONDO calls it Far-East scarlet-like fever
  • HP:0000202 (1 mention) - the report calls it "Oral cavity abnormality"; HP calls it Orofacial cleft

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0007556 (1 mention) - the report calls it "Palmoplantar desquamation"; HP calls it Plantar hyperkeratosis
  • HP:0000206 (1 mention) - the report calls it "Glossitis, related"; HP calls it Glossitis
  • GO:0032609 (1 mention) - the report calls it "interferon-gamma production"; GO calls it type II interferon production, and lists "interferon-gamma production" among its other names
  • CL:0000624 (1 mention) - the report calls it "CD4⁺ T cell"; CL calls it CD4-positive, alpha-beta T cell
  • CL:0000625 (1 mention) - the report calls it "CD8⁺ T cell"; CL calls it CD8-positive, alpha-beta T cell
  • CL:0000794 (1 mention) - the report calls it "CD8⁺ cytotoxic T cell"; CL calls it CD8-positive, alpha-beta cytotoxic T cell, and lists "cytotoxic T cell" among its other names
  • UBERON:0002116 (1 mention) - the report calls it "Primary: terminal ileum"; UBERON calls it ileum**, and lists "intestinum ileum" among its other names
  • UBERON:0002097 (1 mention) - the report calls it "Secondary/systemic: skin"; UBERON calls it skin of body**, and lists "entire skin" among its other names